Literature DB >> 24426223

Unique correlation between mutated citrullinated vimentine IgG autoantibodies and markers of systemic inflammation in rheumatoid arthritis patients.

Walid E Zahran1, Magda I Mahmoud1, Kamal A Shalaby1, Manal H Abbas2.   

Abstract

Rheumatoid arthritis (RA) is the most common inflammatory systemic autoimmune disease, primarily affecting the peripheral joints. Anti-mutated citrullinated vimentin autoantibodies (anti-MCV) of IgG isotype were shown to be a useful diagnostic marker of RA especially in RA patients who were anti-cyclic citrullinated protein autoantibodies (anti-CCP) negative. Nevertheless, published data correlates rheumatoid factor (RF), anti-CCP or anti-MCV antibodies with either erythrocyte sedimentation rate (ESR) or serum C-reactive protein (CRP) as markers of disease activity, not investigated the possible correlations of RA autoantibodies towards ESR and CRP in comparison. Herein, we aim to evaluate the usefulness of anti-MCV as a dependable marker in established RA compared with anti-CCP and RF antibodies and to examine correlations between RF, anti-CCP and anti-MCV antibodies towards ESR and serum CRP. Serum RF-IgA, RF-IgM, anti-CCP and anti-MCV levels were measured in 30 patients with RA and 40 patients with other autoimmune diseases (non-RA) compared with 20 normal subjects. Specificity, sensitivity and AUC for RF antibodies, anti-CCP and anti-MCV were calculated towards RA diagnosis. Our results showed that ESR and CRP had significantly higher values in both RA and non-RA patients compared with our healthy controls with observed significant increment in RA patients compared with non-RA patients. An important finding from our study is that 33.3 % of RA patients were anti-CCP negative but being positive towards anti-MCV. Also, in-between 36.7 up to 40 % of RA patients were RF-IgA and RF-IgM negative while being anti-MCV positive. Anti-MCV antibodies showed the highest specificity and sensitivity (97.5 and 86.6 %, respectively) towards RA diagnosis with the highest AUC value (0.920) compared with anti-CCP and RF antibodies. Correlation analyses revealed that there was no significant correlation between ESR along with CRP towards RF-IgA, RF-IgM and anti-CCP while profound highly significant correlation exhibited between ESR and CRP towards anti-MCV data (r = 0.879 and 0.994, respectively). Thus, our data suggest that the assessment of serum anti-MCV autoantibodies along with ESR and CRP considered as a simple laboratory regime for monitoring RA patients to assess and follow-up disease activity. The addition of anti-MCV autoantibodies to serologic markers in the ACR/EULAR classification criteria for RA will add points for patients with negative anti-CCP and RF antibodies.

Entities:  

Keywords:  Anti-mutated citrullinated vimentine antibodies; C-reactive protein; Erythrocyte sedimentation rate; Rheumatoid arthritis; Sensitivity; Specificity

Year:  2012        PMID: 24426223      PMCID: PMC3689334          DOI: 10.1007/s12291-012-0272-1

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  26 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.

Authors:  Linda Mathsson; Mohammed Mullazehi; Marius C Wick; Olof Sjöberg; Ronald van Vollenhoven; Lars Klareskog; Johan Rönnelid
Journal:  Arthritis Rheum       Date:  2008-01

3.  Anti-modified citrullinated vimentin (MCV) antibodies in patients with very early synovitis.

Authors:  Karim Raza; Linda Mathsson; Christopher D Buckley; Andrew Filer; Johan Rönnelid
Journal:  Ann Rheum Dis       Date:  2009-10-20       Impact factor: 19.103

4.  Diagnostic value of antibodies to modified citrullinated vimentin in early rheumatoid arthritis.

Authors:  Lyudmila Sizova
Journal:  Hum Immunol       Date:  2012-02-02       Impact factor: 2.850

5.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis.

Authors:  L Damjanovska; M M Thabet; E W N Levarth; G Stoeken-Rijsbergen; E I van der Voort; R E M Toes; T W J Huizinga; A H M van der Helm-van Mil
Journal:  Ann Rheum Dis       Date:  2009-05-17       Impact factor: 19.103

7.  Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.

Authors:  Holger Bang; Karl Egerer; Anke Gauliard; Kirsten Lüthke; Paul E Rudolph; Gert Fredenhagen; Wigbert Berg; Eugen Feist; Gerd-R Burmester
Journal:  Arthritis Rheum       Date:  2007-08

8.  A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis.

Authors:  Peter Taylor; Juliane Gartemann; Jeanie Hsieh; James Creeden
Journal:  Autoimmune Dis       Date:  2011-09-11

9.  Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.

Authors:  Pascale Nicaise Roland; Sabine Grootenboer Mignot; Alessandra Bruns; Margarita Hurtado; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Olivier Meyer; Sylvie Chollet Martin
Journal:  Arthritis Res Ther       Date:  2008-12-10       Impact factor: 5.156

10.  Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.

Authors:  Erik R Vossenaar; Normand Després; Elvy Lapointe; Annemarie van der Heijden; Maximillian Lora; Tatsuo Senshu; Walther J van Venrooij; Henri A Ménard
Journal:  Arthritis Res Ther       Date:  2004-02-05       Impact factor: 5.156

View more
  3 in total

1.  Immunodiagnostic significance of anti-RA33 autoantibodies in Saudi patients with rheumatoid arthritis.

Authors:  Jamil A Al-Mughales
Journal:  J Immunol Res       Date:  2015-03-25       Impact factor: 4.818

2.  Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis.

Authors:  Luisa Lindenberg; Lydia Spengler; Holger Bang; Thomas Dorner; Aleksej L Maslyanskiy; Sergey V Lapin; Elena I Ilivanova; Lorena Martinez-Gamboa; Hans Bastian; Esther Wittenborn; Karl Egerer; Gerd-R Burmester; Eugen Feist
Journal:  Arthritis Res Ther       Date:  2015-08-13       Impact factor: 5.156

3.  Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.

Authors:  Goitybell Martínez; Jorge A Gómez; Holger Bang; Lorena Martínez-Gamboa; Dirk Roggenbuck; Gerd-Rüdiger Burmester; Barbara Torres; Dinorah Prada; Eugen Feist
Journal:  Rheumatol Int       Date:  2016-04-02       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.